title: Impact of immunoreactive substances contained in apheresis platelet concentrate on postoperative respiratory function in surgical patients receiving platelet transfusion: a prospective cohort study.
abstract: OBJECTIVE
  To construct an alternative policy for the donor selection of platelet concentrate (PC), a clinical study exploring the features of lung injury following PC administration is needed.
  
  
  BACKGROUND
  Although a male-donor-only policy for plasma products appears to have efficiently reduced transfusion-related acute lung injury (TRALI), this policy may not be applied to PC because of supply shortages.
  
  
  METHODS
  We prospectively examined pulmonary function after the transfusion of PC in informed surgical patients treated at a tertiary university hospital in Japan. The contributions of immunoreactive substances contained in the PC to respiratory function after PC transfusion was then statistically examined.
  
  
  RESULTS
  Eighty-six patients (56 men, 30 women) were enrolled in the analysis. Fifty-four cases experienced respiratory failure (PaO2 /FiO2 <300 mmHg) after transfusion. Five cases were diagnosed as possible TRALI based on permeability pulmonary oedema, while 23 cases were diagnosed as transfusion-associated circulatory overload (TACO) based on chest radiograph findings. A multivariate logistic regression analysis identified the presence of anti-granulocyte antibody as a significant predictor of possible TRALI [P = 0.023; odds ratio (OR), 13.0; 95% confidence interval (CI), 1.4-118.3]. Meanwhile, anti-leukocyte antibody class II was identified as a significant independent predictor of TACO (P = 0.010; OR, 18.4; 95% CI, 2.0-170.1).
  
  
  CONCLUSIONS
  Our data suggest that antibodies contained in PC may contribute to the deterioration of respiratory function after PC transfusion, although the diagnoses of TACO and TRALI may have overlapped among the patients with pulmonary distress in this cohort.
authors.affiliation: Departments of Anesthesiology, Kyorin University School of Medicine.
authors.forename: R
authors.initials: R
authors.lastname: Kanai
authors.forename: T
authors.initials: T
authors.lastname: Iijima
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: H
authors.initials: H
authors.lastname: Nakazawa
authors.forename: H
authors.initials: H
authors.lastname: Ohnishi
authors.forename: T
authors.initials: T
authors.lastname: Yorozu
authors.forename: R
authors.initials: R
authors.lastname: Ohkawa
authors.forename: T
authors.initials: T
authors.lastname: Nojiri
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Okazaki
mesh_terms: D055371:Acute Lung Injury / Q000209:etiology* / Q000276:immunology*; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion / Q000009:adverse effects*; D010983:Plateletpheresis; D011446:Prospective Studies
keywords: LPC; TACO; TRALI; anti-HLA antibody; platelet; platelet concentrate; pulmonary distress; transfusion